Research progress of microRNAs suppressing tumorigenesis through Hippo signaling

doi:10.16352/j.issn.1001-6325.2023.12.1871

Abstract

Abstract: The aberrant activation of yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), downstream effectors of the Hippo signaling pathway, has been implicated in hepatocellular carcinoma(HCC). The microRNAs (miRNAs) works as a tumor suppressors that influence the proliferation, migration and apoptosis of tumor cells by modulating Hippo-YAP/TAZ signaling during hepatic tumorigenesis. Exploring the role of miRNAs in regulating Hippo YAP/TAZ pathway in HCC can provide new ideas for the diagnosis and treatment of HCC.

Key words: hepatocellular carcinoma, Hippo pathway, microRNAs, molecular mechanism

CLC Number:

R735.7

CHA Na, HAO Dandan, LI Tianzhu. Research progress of microRNAs suppressing tumorigenesis through Hippo signaling[J]. Basic & Clinical Medicine, 2023, 43(12): 1871-1875.

References 25

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71:209-249.
[2]	Hayashi H, Higashi T, Yokoyama N, et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression[J]. Cancer Res, 2015,75:4985-4997.
[3]	Wang T, Qin ZY, Wen LZ, et al. Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells[J]. Cell Death Differ, 2018,25:2086-2100.
[4]	Chen M, Wu L, Tu J, et al. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression[J]. EBioMedicine, 2018,35:142-154.
[5]	Xie SC, Zhang JQ, Jiang XL, et al. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma[J]. Cell Death Dis, 2020,11:676. doi:10.1038/s41419-020-02853-8.
[6]	Gao R, Kalathur R, Coto-Llerena M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis[J]. EMBO Mol Med, 2021,13:e14351. doi:10.15252/emmm.202114351.
[7]	Qin Y, Pei Z, Feng Z, et al. Oncogenic activation of YAP signaling sensitizes ferroptosis of hepatocellular carcinoma via ALOXE3-mediated lipid peroxidation accumulation[J]. Front Cell Dev Biol, 2021,9:751593. doi:10.3389/fcell.2021.751593.
[8]	Zhou Y, Wang Y, Zhou W, et al. YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway[J]. Cancer Cell Int, 2019,19:179. doi:10.1186/s12935-019-0898-7.
[9]	Zhang H, Yu QL, Meng L, et al. TAZ-regulated expression of IL-8 is involved in chemoresistance of hepato-cellular carcinoma cells[J]. Arch Biochem Biophys, 2020,693:108571. doi:10.1016/j.abb.2020.108571.
[10]	Sun T, Mao W, Peng H, et al. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin[J]. Cell Oncol (Dordr), 2021,44:689-699.
[11]	张春艳, 张富春, 马纪, 等. microRNA与肝癌[J]. 基础医学与临床, 2016,36:1429-1432
[12]	Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties[J]. Biochem Biophys Res Commun, 2010,394:623-627.
[13]	Ruan T, He X, Yu J, et al. MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma[J]. Oncol Lett, 2016,11:2941-2945.
[14]	Makino Y, Hikita H, Kodama T, et al. CTGF mediates tumor-stroma interactions between hepatoma cells and hepatic stellate cells to accelerate HCC progression[J]. Cancer Res, 2018,78:4902-4914.
[15]	Wang Y, Cui M, Sun BD, et al. MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3′UTR[J]. Acta Pharmacol Sin, 2014,35:1207-1214.
[16]	Lei CJ, Li L, Gao X, et al. Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP[J]. Cell Biochem Funct, 2015,33:326-333.
[17]	Lei CJ, Yao C, Li DK, et al. Effect of co-transfection of miR-520c-3p and miR-132 on proliferation and apoptosis of hepatocellular carcinoma Huh7[J]. Asian Pac J Trop Med, 2016,9:898-902.
[18]	Zhang L, Yu Z, Xian Y, et al. microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma[J]. FEBS Open Bio, 2016,6:155-164.
[19]	Higashi T, Hayashi H, Ishimoto T, et al. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells[J]. Br J Cancer, 2015,113:252-258.
[20]	Li J, Fang L, Yu W, et al. MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif[J]. Oncol Lett, 2015,9:1971-1975.
[21]	Liu P, Zhang H, Liang X, et al. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma[J]. Oncotarget, 2015,6:29048-29059.
[22]	He Y, Hwang S, Cai Y, et al. MicroRNA-223 amelio-rates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes[J]. Hepatology, 2019,70:1150-1167.
[23]	Yang X, Yin J, Yu J, et al. miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w[J]. Oncol Rep, 2012,27:250-257.
[24]	Yang X, Yu J, Yin J, et al. MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2[J]. Pharmazie, 2012,67:645-651
[25]	Wu H, Zhang W, Wu Z, et al. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma[J]. Cell Death Dis, 2019,10:48. doi:10.1038/s41419-018-1281-7.